The Covid-19 epidemic highlighted the disproportionate way the virus impacted minority communities across the U.S., increasing the calls for racial and ethnic diversity in clinical studies. While there has been a more significant push, a recent Pfizer clinical trials diversity report shows there is still a wide gap that needs to be bridged.
With global attention on gender and racial inequities this year, the Healthcare Businesswomen’s Association (HBA) is proud to recognize BD (Becton, Dickinson and Company) GSK, Surgical Care Affiliates and Walgreens Boots Alliance with 2020 ACE Awards for exemplary workplace initiatives that are working to close the gender and racial inequities in the healthcare and life sciences industry.
As the United States continues to grapple with race issues in the wake of the death of George Floyd, the leaders of Heartbeat issued their own call for more diversity and inclusion within the healthcare advertising industry, and within Heartbeat in particular.
A recent report in the New England Journal of Medicine reveals that the racial and ethnic minority groups most negatively impacted by Covid-19 are also the least represented in these clinical studies to develop vaccines and therapeutics aimed at the disease.
Numerous studies have found that in the U.S., minorities such as African Americans, Hispanics and Native Americans are often underrepresented in clinical trials. Regulatory agencies and various organizations are making an effort to address this issue.
Total U.S. coronavirus cases surpassed 2 million, according to a Reuters tally, as health officials urge anyone who took part in massive protests for racial justice to get tested.
In a first-of-its-kind effort, the Biotechnology Innovation Organization (BIO) conducted a survey that attempts to dive into diversity within the pharmaceutical and biotech industry.